2022, Number 1
Treatment of recurrent aphthous stomatitis in immunocompromised patients. Systematic review
Language: Spanish
References: 25
Page: 120-137
PDF size: 285.83 Kb.
ABSTRACT
Background: Although recurrent aphthous stomatitis does not have a well-defined etiology due to it is a multicausal disease, it has been recognized that the interactions or the weakening of the immune system, contribute mainly to the magnitude of the process pathological. Treatment proposals in immune compromised patients are diverse and they usually focus on specific immunological alterations.Objective: To evaluate the clinical effect of the proposed treatments for recurrent aphthous stomatitis in immunocompromised patients.
Methodology: The search was performed in the PubMed/Medline and Cochrane databases. Clinical trials were included that could have among their main response variables: Aphthous ulcer healing, healing time, recurrence and pain intensity and among the secondary variables: Adverse effects and symptoms. data extraction was done independently by the authors. The methodology was applied by Cochrane collaboration to assess the risk of bias in each of the studies.
Results: 11 clinical trials (8 controlled) published between 1995 and 2020 and that provided the results of the efficacy of various therapeutic interventions: thalidomide (4), irsogladine (2), rebamipide (1), diode laser (1), Omega-3 capsules (1), vitamin B 12 (1), Complex B (1). Six of these studies included patients with the minor form of stomatitis recurrent aphthous. The follow-up period was between 14 and 360 days.
Conclusions: Thalidomide may be effective in relieving symptoms, healing and remission of the lesions, the laser diode and vitamin B12 in the decrease of the intensity of the pain.
REFERENCES
Queiroz SIML, Silva MVA, Medeiros AMC, Oliveira PT, Gurgel BCV, Silveira EJD. Recurrent aphthous ulceration: an epidemiological study of etiological factors, treatment and differential diagnosis. An Bras Dermatol [Internet]. 2018 [cited 2021 Jan 10];93(3):341-6. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001102/pdf/abd-93-03-0341.pdf
Ruan HH, Li GY, Duan N, Jiang HL, Fu YF, Song YF, et al. Frequencies of abnormal humoral and cellular immune component levels in peripheral blood of patients with recurrent aphthous ulceration. J Dent Sci. [Internet]. 2018 [cited 2021 Jan 10];13(2):124-130. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388805/pdf/main.pdf
Grimaux X, Leducq S, Goupille P, Aubourg A, Miquelestorena-Standley E, Samimi M. Aphthous mouth ulcers as an initial manifestation of sécukinumab-induced inflammatory bowel disease. Ann Dermatol Venereol [Internet]. 2018 Nov [cited 2021 Jan 15];145(11):676-682. Available from: Available from: https://www.sciencedirect.com/science/article/abs/pii/S015196381830499X?via%3Dihub
Tekcan A, Yigit S, Nursal AF, Tumer MK, Yerliyurt K, Kuruca N. Analysis Of İnterleukin-1 Receptor Antagonist Variable Number Tandem Repeat Variant in Recurrent Aphthous Stomatitis. Endocr Metab Immune Disord Drug Targets [Internet]. 2021 [cited 2021 Sep 18];21(1):139-44. Available from: Available from: https://pubmed.ncbi.nlm.nih.gov/32282310/
Ding X, Xu F, Zhang X. Clinical therapeutic effects of topical agents in adult patients with human immunodeficiency virus-related oral mucosa ulcers. Medicine (Baltimore) [Internet]. 2021 [cited 2021 Sep 18];100(6). Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886410/pdf/medi-100-e23626.pdf
Nur'aeny N, Gurnida DA, Suwarsa O, Sufiawati I. The Impact of DNA Methylation on IL6 mRNA Levels in Hematinic Deficiency and Atopy-Associated Recurrent Aphthous Stomatitis Patients. Int J Dent [Internet]. 2021 [cited 2021 Sep 18];2021:1-11. Available from: Available from: https://downloads.hindawi.com/journals/ijd/2021/5560695.pdf
Yang Z, Cui Q, An R, Wang J, Song X, Shen Y, et al. Comparison of microbiomes in ulcerative and normal mucosa of recurrent aphthous stomatitis (RAS)-affected patients. BMC Oral Health [Internet]. 2020 [cited 2021 Jan 10];20(1):128. Available from: Available from: https://bmcoralhealth.biomedcentral.com/articles/10.1186/s12903-020-01115-5
Paterson DL, Georghiou PR, Allworth AM, Kemp RJ. Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. Clin Infect Dis [Internet].1995 Feb [cited 2021 Jan 10];20(2):250-4. Available from: Available from: https://academic.oup.com/cid/article-abstract/20/2/250/376713?redirectedFrom=fulltext
Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. [Internet].1997 [cited 2021 Jan 10];336(21):1487-93. Available from: Available from: https://www.nejm.org/doi/10.1056/NEJM199705223362103?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0www.ncbi.nlm.nih.gov
Jacobson JM, Greenspan JS, Spritzler J, Fox L, Fahey JL, Jackson JB. Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers. J Infect Dis. [Internet]. 2001 [cited 2021 Jan 10];183(2):343-346. Available from: Available from: https://academic.oup.com/jid/article/183/2/343/850304
Mimura MA, Hirota SK, Sugaya NN, Sanches JA Jr, Migliari DA. Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial. Clinics (Sao Paulo). [Internet]. 2009 [cited 2021 Jan 10];64(3):193-8. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2666466/pdf/cln64_3p0193.pdf
Nanke Y, Kamatani N, Okamoto T, Ogiuchi H, Kotake S. Irsogladine is effective for recurrent oral ulcers in patients with Behçet's disease: an open-label, single-centre study. Drugs R D. [Internet]. 2008 [cited 2021 Jan 10];9(6):455-9. Available from: Available from: https://pubmed.ncbi.nlm.nih.gov/18989994/
Hayashi N, George J, Shiroeda H, Saito T, Toshikuni N, Tsuchishima M, et al. Irsogladine maleate for the treatment of recurrent aphthous stomatitis in hepatitis C virus patients on pegylated-interferon and ribavirin: a pilot study. J Gastroenterol Hepatol [Internet]. 2013 Jun [cited 2021 Jan 10];28(6):1015-8. Available from: Available from: https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgh.12137
Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, Nakamura S, Tanaka S, Kogure M, Mizushima Y. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double-blind, placebo-controlled study. Drugs R D [Internet]. 2003 [cited 2021 Jan 10];4(1):19-28. Available from: Available from: https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgh.12137
Golestannejad Z, Ghalayani P, Mojthaedi N, Foroughi A. The effectiveness of submucosal injection bioactive vitamine b12 in comparision to triancinolone in pain and frecuency of apthous ulcer. Ann Dent Spec [Internet]. 2017 [cited 2021 Jan 10];5(3):122-125. Available from: Available from: https://annalsofdentalspecialty.net.in/storage/models/article/IEpxGJAby2yL8vE6iP8V13lM8Y2XUZEKpuvp7BT316R8D1rgodDjQGGIdewo/9-the-effectiveness-of-submucosal-injection-bioactive-vitamin-b12-in-comparison-to-triaminolone-in.pdf
Rasi A, Zamanian A, Mehran G, Ezati A, Rastin V, Karimi S. Comparing the Effect of Injectable Vitamin B With Conventional Oral Treatment on Aphthous Stomatitis. J Skin Stem Cell [Internet]. 2018 [cited 2021 Jan 10];5(1-2):e69052. Available from: Available from: https://sites.kowsarpub.com/jssc/articles/69052.html